PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

Similar documents
1. What Panzyga is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

PACKAGE LEAFLET: INFORMATION FOR THE USER

2. What do you need to know before you use Octanate

1 WHAT OCTAGAM 50 mg/ml IS AND WHAT IT IS USED FOR

Package leaflet: Information for the user

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Tiorfan Hidrasec Tiorfix Tiorfast 100 mg PACKAGE LEAFLET

Package leaflet: Information for the patient. Avodart 0.5 mg soft capsules dutasteride

(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS

CONSUMER MEDICINE INFORMATION LEAFLET

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Zoviduo 50 mg/g and 10 mg/g cream. Aciclovir and Hydrocortisone

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets

Package leaflet: Information for the user

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Package leaflet: Information for the user Salofalk 500mg gastro-resistant tablets Mesalazine

Package Leaflet: Information for the Patient. FOSRENOL 750 mg oral powder. FOSRENOL 1000 mg oral powder. lanthanum

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

1. What Miacalcic is and what it is used for

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

Package leaflet: information for the user

Package leaflet: Information for the user Oftaquix 5 mg/ml eye drops, solution. Levofloxacin

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

PACKAGE LEAFLET: INFORMATION FOR THE USER

1 What Engerix B is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)

Package leaflet: Information for the user. Norditropin SimpleXx 5 mg/1.5 ml solution for injection in cartridge somatropin

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

PACKAGE LEAFLET: INFORMATION FOR THE USER Meronem IV 500 mg and 1 g Powder for solution for injection or infusion meropenem

Package Leaflet: Information for the Patient. FOSRENOL 750 mg chewable tablets. FOSRENOL 1000 mg chewable tablets. lanthanum

PACKAGE LEAFLET: INFORMATION FOR THE USER

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

Package leaflet: Information for the user. Relestat, 0.5 mg/ml, eye drops, solution Epinastine hydrochloride

Package leaflet: Information for the user. Dalmevin 50 mg tablets Vildagliptin

SUMMARY OF PRODUCT CHARACTERISTICS

PACKAGE LEAFLET: INFORMATION FOR THE USER. Naltrexone 50 mg film-coated tablets (Naltrexone hydrochloride)

Package leaflet: Information for the user. Lescol 20 and 40 mg hard capsules. Fluvastatin

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

Package leaflet: Information for the user

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin

Package leaflet: Information for the user. Recikalc-D forte 500 mg/800 IU chewable tablets. Calcium/cholecalciferol (Vitamin D3)

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER ACULAR 0.5% w/v EYE DROPS, SOLUTION (Ketorolac trometamol)

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride

Flavamed Forte 30 mg/5 ml, oral solution

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Technescan MIBI 1 mg, kit for radiopharmaceutical preparation

1. What Naropin is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER. NEFOXEF 120 MG FILM-COATED TABLETS NEFOXEF 180 MG FILM-COATED TABLETS Fexofenadine hydrochloride

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol

PACKAGE LEAFLET: INFORMATION FOR THE USER. STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live)

Voluven 10 % solution for infusion Hydroxyethyl starch (HES 130/0.4) in isotonic sodium chloride solution

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the user. Paralink 10 mg/ml Solution for Infusion Paracetamol

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the user. Compound Macrogol Oral Powder Sugar Free

Lovastatin tablets 20 and 40 mg PACKAGE LEAFLET

Package Leaflet: Information for the User. Zomig Rapimelt 2.5 mg and 5 mg orodispersible tablets zolmitriptan

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)

Package leaflet: Information for the user. Rapydan 70mg/70mg medicated plaster. Lidocaine/Tetracaine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Adrenaline

Package Leaflet: Information for the User

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package leaflet: Information for the patient

SUMMARY OF PRODUCT CHARACTERISTICS

Package Leaflet: Information for the patient. Movicol Ready to Take oral solution in sachet

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

ANNEX III LABELLING AND PACKAGE LEAFLET

Package leaflet: Information for the patient

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.

PATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml

Package leaflet: Information for the user. Salofalk 3g gastro-resistant prolonged-release granules. Mesalazine

Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate

Package Leaflet: Information for the user Laxido Paediatric Plain 6.9 g, powder for oral solution

Package leaflet: Information for the user. Irprestan 150 mg film-coated tablets. Irprestan 300 mg film-coated tablets irbesartan

NITHIODOTE Solution for Injection. Active Substances Sodium Nitrite and Sodium Thiosulfate

Package leaflet: Information for the user. Chirocaine mg/ml or 1.25 mg/ml solution for infusion For epidural use only.

Package leaflet: Information for the user. GLUCOPHAGE 500 mg powder for oral solution in sachets metformin hydrochloride

What is in this leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone

PACKAGE LEAFLET: INFORMATION FOR THE USER. Ondansetron BMM Pharma 8 mg film-coated tablets. Ondansetron

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the user. Iron

The medicines you are using mixed with Water for injections may interact with each other.

Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

PACKAGE LEAFLET: INFORMATION FOR THE USER

Transcription:

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Albunorm 20% is and what it is used for 2. Before you use Albunorm 20% 3. How to use Albunorm 20% 4. Possible side effects 5. How to store Albunorm 20% 6. Further information 1. WHAT ALBUNORM 20% IS AND WHAT IT IS USED FOR Albunorm 20% belongs to the pharmacotherapeutic group: blood substitutes and plasma protein fractions. The product is given to patients to restore and maintain circulating blood volume where a deficiency in volume has been demonstrated. 2. BEFORE YOU USE ALBUNORM 20% Do not use Albunorm 20% if you are allergic (hypersensitive) to human albumin preparations or any of the other ingredients of Albunorm 20% 666_UK_pil_03_20101117 1/ 5

Take special care with Albunorm 20% if you are at special risk from increased blood volume e.g. in case of severe heart disorders, high blood pressure, dilated veins of the oesophagus, fluid in the lung, bleeding disorders, severely lowered red blood cell count or without urine output. when there are signs for increased blood volume (headache, breathing disorder, jugular vein congestion) or increased blood pressure. The infusion should be stopped immediately. when there are signs of an allergic reaction. The infusion should be stopped immediately. when it is used in patients with severe traumatic brain injury. Virus safety When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include: careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded testing of each donation and pools of plasma for signs of virus/infections steps included by the manufacturers in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections. There are no reports of virus infections with albumin manufactured to European Pharmacopoeia specifications by established processes. It is strongly recommended that every time you receive a dose of Albunorm 20% the name and batch number of the product are recorded in order to maintain a record of the batches used. Using other medicines No interactions of human albumin with other products are known so far. However, Albunorm 20% solution should not be mixed in the same infusion with other drugs, whole blood or packed red cells. Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Pregnancy and breast-feeding Human albumin is a normal constituent of human blood. No harmful effects are known when this product is used during pregnancy or breast-feeding. Particular care should be taken to adjust blood volume in pregnant women. Ask your doctor for advice before taking any medicine. 666_UK_pil_03_20101117 2/ 5

Driving and using machines There are no indications that human albumin impairs the ability to drive or to operate machines. Important information about some of the ingredients of Albunorm 20% This product contains sodium and potassium and may be harmful to people on a low sodium or potassium diet. Tell your doctor if this applies to you. 3. HOW TO USE ALBUNORM 20% Albunorm 20% is ready for use as an infusion ( drip ) into a vein. The dosage and infusion rate (how quickly you are given albumin into a vein) will depend on your particular condition. Your doctor will decide what treatment is best for you. Instructions The product should be brought to room or body temperature before use. The solution should be clear and should not have a deposit. Any unused solution should be discarded. If you have any further questions on the use of this product, ask your doctor or pharmacist. If you use more Albunorm 20% than you should If the dosage and rate of infusion are too high, you may develop headache, high blood pressure and discomfort breathing. The infusion should be stopped immediately and your doctor will decide if any other treatment is necessary. 4. POSSIBLE SIDE EFFECTS Like all medicines, Albunorm 20% can cause side effects, although not everybody gets them. Side effects after infusion of human albumin are rare and they normally disappear when the infusion-rate is slowed down or stopped. Rare: affects 1 to 10 users in 10,000: Flush, urticaria, fever and nausea. Very rare: affects less than 1 user in 10,000: Shock due to hypersensitivity reaction. 666_UK_pil_03_20101117 3/ 5

Frequency not known: cannot be estimated from the available data: Confusional state; headache; increased or decreased heart rate; high blood pressure or low blood pressure; heat sensation; shortage of breath; nausea; nettle rash; swelling around eyes, nose, mouth; rash; increased sweating; fever; chills. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 5. HOW TO STORE ALBUNORM 20% Keep out of the reach and sight of children. Do not use Albunorm 20% after expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month. Do not store above 25 C. Store in the original package in order to protect from light. Do not freeze. Once the infusion container has been opened, the content should be used immediately. The solution should be clear or slightly opalescent. Do not use solutions which are cloudy or have deposits. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. 6. FURTHER INFORMATION What Albunorm 20% contains The active substance is 200 g/l human albumin derived from human plasma (bottle of 50, 100 ml). The other ingredients are sodium chloride, N-Acetyl-DL-tryptophan, caprylic acid and water for injections. What Albunorm 20% looks like and contents of the pack: Albunorm 20% is a solution for infusion in a bottle (50 ml - pack size of 1 and 10) Albunorm 20% is a solution for infusion in a bottle (100 ml - pack size of 1 and 10) The solution is clear, yellow, amber or green. Not all pack sizes may be marketed in all countries. 666_UK_pil_03_20101117 4/ 5

Marketing Authorisation Holder: Octapharma Ltd. The Zenith Building 26 Spring Gardens Manchester M2 1AB United Kingdom This medicinal product is authorised in the Member States of the EEA under the following names: Albunorm: Denmark, Italy Albunorm 20%: Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Ireland, Iceland, Luxemburg, Malta, Netherlands, Poland, Portugal, Slovak Republic, Spain, United Kingdom Albunorm 200 g/l: Austria, Estonia, Greece, Finland, France, Hungary, Latvia, Lithuania, Norway, Romania, Sweden, Slovenia Manufacturers: Octapharma Pharmazeutika, Produktionsges.m.b.H., Oberlaaerstrasse 235, 1100 Vienna, Austria Octapharma S.A.S., 72 rue du Maréchal Foch, 67380 Lingolsheim, France Octapharma AB, Elersvägen 40, 112 75 Stockholm, Sweden Octapharma Produktionsgesellschaft Deutschland mbh, Wolfgang-Marguerre-Allee 1, 31832 Springe, Germany Octapharma GmbH, Elisabeth-Selbert-Str. 11, 40764 Langenfeld, Germany This leaflet was last approved in 05/2011. 666_UK_pil_03_20101117 5/ 5